Feed / TEVA

Teva Pharmaceutical Industries

TEVA

Healthcare · 35.00 -1.1% today

Jodie read · what matters now

Revenue increased 2.3% versus the comparable filing period.

The story is only the start. Jodie keeps watching the filing evidence, the companies connected to TEVA, and whether its market group begins moving.

Latest storyNo Struct brief yetJodie is monitoring new filings.
Disclosed connections31 verified links28 additional receipts in Pro
Organic co-movement groupGeneric Pharmaceuticals · LeaderLast observed group; it is between live snapshots · See active groups →

Latest filing assessment · baseline

The latest filing presents a mixed picture

10-Q filed 2026-04-29 against the comparable filing from 2025-05-07.

mixed
OperationsconstructiveEvidence score +3
liquiditycautiousEvidence score -1
valuationmixed

What improved

  • Revenue increased 2.3% versus the comparable filing period.
  • Operating margin improved 3.0 percentage points.
  • Net income increased 72.4% versus the comparable filing period.

What weakened

  • Operating cash flow covered only -0.11x net income.

Filing receipts

The lower cash flow used in operating activities in the first quarter of 2026 was mainly due to favorable timing and mix of sales and collections in our U.S. segment as well as lower payments of interest, partially offset by higher performance incentive payments to employees.

In local currency terms, revenues decreased by 14%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.

In local currency terms, revenues decreased by 2%, mainly due to net price reductions and lower volumes.

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Who this business touches

The relationships behind TEVA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ALVOFiling-linked namepartnerFull receipt with Pro →
RPRXRoyalty Pharma plcpartnerFull receipt with Pro →

Depended on by

HALOHalozyme Therapeutics, Inc.supplierFull receipt with Pro →

Filing peers

Companies whose filings use similar operating language.

You can see the shape of the network here. Pro opens 28 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →

What is moving around it

Live connections

TEVA is currently a Leader in the organic co-movement group Generic Pharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for TEVA; it is not active in the latest market snapshot.

Theme membership history

No durable theme membership has been observed for this name yet.